Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity nudges up target price on Marks Electrical

(Sharecast News) - Analysts at Canaccord Genuity nudged up their target price on Marks Electrical from 70.0p to 73.0p on Thursday after the group reported full-year revenues had grown. Marks posted FY revenue growth of 2.6% to £117.2m, with Canaccord noting that adjusted underlying earnings were also ahead of its estimates at £4.2m, and that net cash was better than expected at £8.8m, reflecting improvements to working capital.

"After a tough H2, Marks has exited FY25 in a far stronger operational position, while the top line has returned to growth in Q4, with a March revenue growth exit rate of +6.6%, stronger than our FY26 forecast with weaker comparatives through the year," said the Canadian bank.

However, Canaccord stated it was making no changes to its FY26-27 estimates, despite the beat and strong start to FY26.

"Post a year of investment and transition, we believe Marks Electrical is coming out the other side in a far stronger place to scale," said Canaccord, which also reiterated its 'buy' recommendation on the stock.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.